title: Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.
abstract: The human inflammatory response can result in the alteration of drug clearance through effects on metabolizing enzymes or transporters. In this article we briefly review the theory of how cancer can lead to indirect changes in drug metabolism, review acute phase proteins and cytokines as markers of changes in cytochrome P450 (CYP) activity in cancer patients, and provide clinical case examples of how the inflammation in advanced cancer patients can lead to altered CYP-mediated drug clearance.
authors: Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana, USA.
authors: D E
authors: DE
authors: Coutant
authors: Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana, USA.
authors: P
authors: P
authors: Kulanthaivel
authors: Pharmacokinetics and Pharmacodynamics, Eli Lilly and Company, Indianapolis, Indiana, USA.
authors: P K
authors: PK
authors: Turner
authors: Pharmacokinetics and Pharmacodynamics, Eli Lilly and Company, Indianapolis, Indiana, USA.
authors: R L
authors: RL
authors: Bell
authors: Pharmacokinetics and Pharmacodynamics, Eli Lilly and Company, Indianapolis, Indiana, USA.
authors: J
authors: J
authors: Baldwin
authors: Department of Statistics-Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA.
authors: S R
authors: SR
authors: Wijayawardana
authors: Pharmacokinetics and Pharmacodynamics, Eli Lilly and Company, Indianapolis, Indiana, USA.
authors: C
authors: C
authors: Pitou
authors: Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana, USA.
authors: S D
authors: SD
authors: Hall
mesh_terms: D000209:Acute-Phase Proteins / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007211:Indoles / Q000493:pharmacokinetics; D007249:Inflammation / Q000378:metabolism; D015201:Meta-Analysis as Topic; D008874:Midazolam / Q000493:pharmacokinetics; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism*; D064546:Protein Kinase C beta / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000494:pharmacology; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D000209:Acute-Phase Proteins; D016207:Cytokines; D007093:Imidazoles; D007211:Indoles; D011725:Pyridines; C580958:ralimetinib; D003577:Cytochrome P-450 Enzyme System; D064546:Protein Kinase C beta; D048051:p38 Mitogen-Activated Protein Kinases; D008874:Midazolam; C504878:enzastaurin